Why the study?
Does bivalirudin improve rates of ischemia and bleeding in patients with moderate- or high-risk acute coronary syndromes undergoing invasive treatment compared to heparin?
Does bivalirudin improve rates of ischemia and bleeding in patients with moderate- or high-risk acute coronary syndromes undergoing invasive treatment compared to heparin?
In patients with moderate- or high-risk acute coronary syndromes undergoing invasive management, bivalirudin alone provides similar ischemic protection with significantly less bleeding compared to heparin.
Supports bivalirudin monotherapy in moderate/high-risk ACS; extends RCT evidence favoring lower bleeding without ischemic trade-off.
In patients with moderate- or high-risk acute coronary syndromes who were undergoing invasive treatment with glycoprotein IIb/IIIa inhibitors, bivalirudin was associated with rates of ischemia and bleeding that were similar to those with heparin. Bivalirudin alone was associated with similar rates of ischemia and significantly lower rates of bleeding. (ClinicalTrials.gov number, NCT00093158 [ClinicalTrials.gov].).
No takes yet. Share an insight, caveat, or question.
Stone et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: